44
Participants
Start Date
October 15, 2014
Primary Completion Date
March 2, 2017
Study Completion Date
April 14, 2017
Atomoxetine 80 MG
Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston
VA Office of Research and Development
FED